Shanghai Pharmaceutical Big Health Yunshang, formed in March with $100m of its parent company's cash, has raised another $174m in a round backed by JD.com and IDG Capital.

Gene therapy developer RegenXBio, backed by investors including GlaxoSmithKline, has so far raised more than $110m in venture funding.

The nucleic acid drug developer previously secured $18m in a series A round backed by contract research company SNBL in February 2015.

The Delta Electronics-backed company, which has developed an artificial heart for transplants, has filed for a $40m initial public offering on Nasdaq.

Existing investor Tate and Lyle returned to back the UC Davis spinout's latest round, which will fund pre-commercialisation activities for its probiotics products.

The startup fund has already backed Cambridge spinout BMLL and hopes to fundraise more money and add other spinouts to its portfolio.

Existing investor Tate and Lyle returned to back Evolve BioSystems' latest round, which will fund pre-commercialisation activities for its probiotics products.

Newly launched genomics company Helix has secured investment from founding partners including Illumina, and additional cash from strategic partner Mayo Clinic.